Compare Novo Nordisk A/S (NVO) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Trade Desk Inc — how do they compare? Novo Nordisk A/S trades at $45.11 (market cap $200.69B), while Trade Desk Inc trades at $13.9 (market cap $6.59B). The key difference: Novo Nordisk A/S is far larger — about 30.5× Trade Desk Inc's market cap, and Novo Nordisk A/S pays a 3.98% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals.
| NVO | TTD | |
|---|---|---|
Market Cap | $200.69B | $6.59B |
Sector | Health | Technology |
52-Week High | $63.98 | $54.13 |
52-Week Low | $35.29 | $13.03 |
Enterprise Value | $215.49B | $5.54B |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
The Trade Desk (TTD) trades at $14.02, down 2.84% on the day and near its 52-week lows, reflecting significant year-to-date pressure. Recent financials show revenue growth slowing to 3% in Q2 2026 with earnings misses, while the company undergoes a 15% workforce restructuring. Technical indicators signal a bearish trend with mixed momentum oscillators. Despite strong profitability margins, valuation multiples remain compressed amid weak advertising demand and competitive pressures.
Outlook remains cautious with near-term headwinds from soft ad spending and execution risks from restructuring. Long-term opportunities exist in CTV and AI-driven ad platforms, but investor sentiment is divided with analysts showing mixed ratings. The stock trades below consensus price targets, offering potential upside if operational improvements materialize, though volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
